Počet záznamů: 1  

Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases

  1. 1.
    0368597 - ÚEB 2012 RIV NL eng J - Článek v odborném periodiku
    Liebl, J. - Kryštof, Vladimír - Vereb, G. - Takacs, L. - Strnad, Miroslav - Pechan, P. - Havlíček, Libor - Zatloukal, Marek - Fuerst, R. - Vollmar, A. M. - Zahler, S.
    Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases.
    Angiogenesis. Roč. 14, č. 3 (2011), s. 281-291. ISSN 0969-6970. E-ISSN 1573-7209
    Grant CEP: GA ČR GA204/08/0511; GA ČR GA301/08/1649
    Výzkumný záměr: CEZ:AV0Z50380511
    Klíčová slova: Angiogenesis * Cdk * Small molecule Cdk inhibitors * Roscovitine
    Kód oboru RIV: CE - Biochemie
    Impakt faktor: 6.063, rok: 2011

    Small molecular inhibitors of Cyclin dependent kinases (Cdks) are currently being developed as anticancer therapeutics due to their antiproliferative properties. The purine Cdk specific inhibitor (R)-roscovitine (seliciclib, CYC202) represents one of the most promising of these compounds. It is currently evaluated in clinical trials concerning cancer therapy. Recently, we have shown that roscovitine exerts potent antiangiogenic effects and elucidated Cdk5 as a new player in angiogenesis. These findings introduce Cdk5 as novel target for antiangiogenic therapy, and Cdk5 inhibitors as an attractive therapeutic approach. Here, we present the antiangiogenic profile of 15 derivatives of roscovitine in vitro and in vivo and provide structure activity relationships of the roscovitine analogs.
    Trvalý link: http://hdl.handle.net/11104/0202896

     
    Název souboruStaženoVelikostKomentářVerzePřístup
    2011_Liebl_ANGIOGENESIS_281.pdf5671.2 KBJinápovolen
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.